5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)benzylidene]-2-iminothiazolidin-4-one | 349636-49-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)benzylidene]-2-iminothiazolidin-4-one
• 英文别名: 5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzylidene]-2-imino-thiazolidin-4-one；(5Z)-5-[[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl]methylidene]-2-imino-1,3-thiazolidin-4-one
• CAS: 349636-49-3
• 化学式: C₁₇H₁₉N₃O₃S
• 分子量: 345.422
• InChiKey: MEKZMTMFDKDXGT-KAMYIIQDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)benzylidene]-2-iminothiazolidin-4-one 生成 1-[4-(2-imino-4-oxo-thiazolidin-5-ylidenemethyl)-phenyl]-piperidin-4-one
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(1,4-二氧杂-8-氮杂螺[4.5]癸-8-基)苯甲醛 、 假硫代乙内酰脲 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以94%的产率得到5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)benzylidene]-2-iminothiazolidin-4-one
  参考文献：
  名称：

  Synthesis of Heterocycle Substituted 1-Aryl-4-piperidones

  摘要：

  A series of heterocycle substituted 1-aryl-4-piperidones were prepared via Knoevenagel condensations between nitrogen-containing 5-membered heterocycles and benzaldehyde (1) followed by reduction or amination. The oxadiazolidinedione ring was formed by reacting the N-hydroxyurea (10) with methyl chloroformate and sodium hydride.

  DOI：

  10.3987/com-02-9447

文献信息

• Cyclic amine phenyl beta-3 adrenergic receptor agonists
  申请人：——

  公开号：US20020028835A1

  公开（公告）日：2002-03-07

  This invention provides compounds of Formula I having the structure 1 wherein, R 1 , R 2 , R 3 , R 4 , R 5 , T, T 1 , T 2 , and X are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  本发明提供了具有结构1的化合物，其中R1、R2、R3、R4、R5、T、T1、T2和X如前所定义，或其药学上可接受的盐，其在治疗或抑制与胰岛素抵抗或高血糖有关的代谢紊乱（通常与肥胖或葡萄糖不耐症有关）、动脉粥样硬化、胃肠道疾病、神经遗传性炎症、青光眼、眼压增高和频繁排尿方面非常有用；尤其适用于治疗或抑制2型糖尿病。
• CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Wyeth

  公开号：EP1301482A1

  公开（公告）日：2003-04-16
• US6525202B2
  申请人：——

  公开号：US6525202B2

  公开（公告）日：2003-02-25
• US7022716B2
  申请人：——

  公开号：US7022716B2

  公开（公告）日：2006-04-04
• [EN] CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR BETA-3 ADRENERGIQUE D'AMINEPHENYLE CYCLIQUE
  申请人：AMERICAN HOME PROD

  公开号：WO2002006232A1

  公开（公告）日：2002-01-24

  This invention provides compounds of Formula (I) wherein: R?1, R2, R3, R4, R5, T, T1, T2¿, and X are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.